7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.
1. A compound having Formula I:
or a salt thereof wherein
X is S or NH;
U and Y are each O, NH, or Nalkyl;
Z is hydrogen;
R 1 is alkyl;
R 2 is alkyl;
R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
2. The compound of claim 1 , wherein U and Y are NH or Nalkyl.
3. The compound of claim 1 , wherein U and Y are oxygen.
4. A pharmaceutical composition comprising a compound of as in claim 1 and a pharmaceutically acceptable excipient.
5. The composition of claim 4 , wherein the pharmaceutical composition is in the form of a tablet, capsule, pill, or solution for injection.
6. A method of preventing or treating a BDNF and TrkB related disease or condition comprising the administering an effective amount of a pharmaceutical composition of claim 4 , to a subject in need thereof.
7. The method of claim 6 wherein the subject is diagnosed with, exhibiting symptoms of, or at risk of the disease or condition.
8. The method of claim 6 , wherein the disease or condition is depression, schizophrenia, obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, anxiety, amyotrophic lateral sclerosis, Autism spectrum disorders, post-traumatic stress disorder, Alzheimer's disease, Huntington's disease, Rhett syndrome, epilepsy, Parkinson's disease, dementia, diabetic neuropathy, peripheral neuropathy, obesity, or stroke.
9. The method of claim 6 , wherein the disease is depression and the pharmaceutical composition is administered in combination with an anti-depressant.
10. The method of claim 9 , wherein the anti-depressant is a selective serotonin reuptake inhibitor such as citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or vilazodone, a serotonin-norepinephrine reuptake inhibitor such as desvenlafaxine, duloxetine, milnacipran, venlafaxine, a noradrenergic and specific serotonergic antidepressant such as mianserin and mirtazapine, a norepinephrine reuptake inhibitor such as atomoxetine, mazindol, reboxetine, viloxazine, a norepinephrine-dopamine reuptake inhibitor such as bupropion, a selective serotonin reuptake enhancer such as tianeptine and amineptine, a norepinephrine-dopamine disinhibitor such as agomelatine, a tricyclic antidepressant such as amitriptyline, clomipramine, doxepin, imipramine, trimipramine, desipramine, nortriptyline, protriptyline, a monoamine oxidase inhibitor such as isocarboxazid, moclobemide, phenelzine, selegiline, tranylcypromine.